C4 Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. C4 Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 33% to $20,756,000. Profit margin reached -638%. Total operating expenses were $159,787,000.
Profit Margin
| 2018 | 19.36M | -15.71M | -81.14% |
|---|---|---|---|
| 2019 | 21.38M | -34.09M | -159.48% |
| 2020 | 33.19M | -66.33M | -199.83% |
| 2021 | 45.78M | -86.03M | -187.92% |
| 2022 | 31.09M | -126.49M | -406.8% |
| 2023 | 20.75M | -132.49M | -638.34% |
CCCC Income Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Revenue | 20.75M | 31.09M | 45.78M | 33.19M | 21.38M | 19.36M |
Cost of revenue | 117.70M | 7.57M | 2.90M | 77.46M | 47.66M | 0 |
Gross profit | -96.95M | 23.52M | 42.87M | -44.27M | -26.28M | 19.36M |
Operating exp. | ||||||
Research and development | 117.70M | 117.84M | 94.66M | 78.44M | 48.05M | 28.59M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 159.78M | 160.63M | 127.91M | 93.64M | 56.83M | 35.75M |
Operating income | -139.03M | -129.53M | -82.13M | -60.44M | -35.45M | -16.38M |
Other income (expenses), net | 7.81M | 1.35M | -1.75M | -6.51M | 2.15M | -7K |
Income before tax | -131.21M | -128.17M | -83.89M | -66.96M | -33.29M | -15.71M |
Income tax expense | 1.28M | -1.67M | 2.14M | -626K | 804K | 678K |
Net income | -132.49M | -126.49M | -86.03M | -66.33M | -34.09M | -15.71M |
Earnings per share | ||||||
Basic EPS | -2.67 | -2.59 | -1.87 | -1.54 | -0.79 | -1.06 |
Diluted EPS | -2.67 | -2.59 | -1.87 | -1.54 | -0.79 | -1.06 |
| Data source | Data source | Data source | Data source |